Health Canada Approves Mirum’s LIVMARLI for PFIC, Expanding Rare Disease Portfolio
Event summary
- Health Canada authorized LIVMARLI (maralixibat) for cholestatic pruritus in PFIC patients aged 12 months and older.
- Approval covers both oral solution and tablet formulations, offering treatment flexibility.
- Authorization supported by Phase 3 MARCH study data showing significant pruritus reduction (p<0.0001).
- PFIC affects 1 in 50,000–100,000 births in Canada, with severe pruritus as a primary symptom.
The big picture
Mirum Pharmaceuticals continues to strengthen its position in the rare disease market with the Health Canada approval of LIVMARLI for PFIC. This expansion of its therapeutic portfolio aligns with broader industry trends toward specialized treatments for genetic disorders. The approval underscores Mirum’s strategic focus on pediatric cholestatic liver diseases, potentially enhancing its commercial footprint and revenue streams.
What we're watching
- Market Expansion
- Whether Mirum can leverage this approval to increase LIVMARLI’s market penetration in Canada and other regions.
- Pipeline Progress
- The pace at which Mirum advances its clinical-stage pipeline, particularly volixibat for PSC and PBC.
- Competitive Dynamics
- How this approval positions Mirum against competitors in the rare disease space, particularly in pediatric liver diseases.
Related topics